Member access

4-Traders Homepage  >  Shares  >  Mercado Continuo Espanol  >  FAES Farma SA    FAE   ES0134950F36

FAES FARMA SA (FAE)

3
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Mercado Continuo Espanol
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
1.82(c) 1.81(c) 1.815(c) 1.805(c) 1.805(c) Last
186 868 174 274 136 849 99 122 200 995 Volume
+0.55% -0.55% +0.28% -0.55% 0.00% Change
More quotes
Company
Faes Farma SA engages in the manufacture, marketing, and research of pharmaceutical products and raw materials for pharmaceutical use. Its products are for allergies, antihypertensive, dermatological, diabetes, digestive, otorhinolaryngology, osteoarticular, respiratory, women's health, central... 
Sector
Pharmaceuticals
Calendar
03/02Earnings Release
More about the company
Surperformance© ratings of FAES Farma SA
Trading Rating : Investor Rating :
More Ratings
Chart FAES FARMA SA
Duration : Period :
FAES Farma SA Technical Analysis Chart | FAE | ES0134950F36 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 193 M
EBIT 2014 31,1 M
Net income 2014 25,5 M
Debt 2014 10,1 M
Yield 2014 3,14%
Sales 2015 204 M
EBIT 2015 36,6 M
Net income 2015 28,8 M
Finance 2015 8,31 M
Yield 2015 3,35%
PER 2014 17,09
PER 2015 14,58
EV / Sales 2014 2,33x
EV / Sales 2015 2,11x
Capitalization 439 M
More Financials
Latest news on FAES FARMA SA
2014 FAES FARMA : Statement 05/14/2014 (112 k.). Bilastine in Canada: signing of a li..
2014 FAES FARMA : Statement 05/14/2014 (112 k.). Bilastine in Canada: signing of a li..
2013 FAES FARMA SA : Statement 07/24/2013 (24 k.). January-June results.
2012 FAES FARMA SA : Statement 13/12/2012 (20 k). Faes Farma licences bilastine for S..
2012 FAES FARMA SA : Statement 02/07/2012 (19 k). FAES FARMA S.A. informs of the appr..
2012 FAES FARMA SA : ex-dividend day for final dividend
2012 FAES FARMA SA : Statement 26/04/2012 (28 k). FAES FARMA and INVIDA (MENARINI Gro..
2012 FAES FARMA SA : Statement 24/01/2012 (19 k). Bilastine's launch in Brazil.
More news
Sector news Pharmaceuticals - NEC
08:04a Antibiotics firm Motif Bio to tap UK market for cash
01/31 JOHNSON & JOHNSON : Former FDA chief calls J&J misleading on Risperdal
01/30 SANOFI : 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana..
Plus d'actualités du secteur Pharmaceuticals - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF